These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24777276)

  • 1. Risk of relapse phenotype recurrence in multiple sclerosis.
    Kalincik T; Buzzard K; Jokubaitis V; Trojano M; Duquette P; Izquierdo G; Girard M; Lugaresi A; Grammond P; Grand'Maison F; Oreja-Guevara C; Boz C; Hupperts R; Petersen T; Giuliani G; Iuliano G; Lechner-Scott J; Barnett M; Bergamaschi R; Van Pesch V; Amato MP; van Munster E; Fernandez-Bolanos R; Verheul F; Fiol M; Cristiano E; Slee M; Rio ME; Spitaleri D; Alroughani R; Gray O; Saladino ML; Flechter S; Herbert J; Cabrera-Gomez JA; Vella N; Paine M; Shaw C; Moore F; Vucic S; Savino A; Singhal B; Petkovska-Boskova T; Parratt J; Sirbu CA; Rozsa C; Liew D; Butzkueven H;
    Mult Scler; 2014 Oct; 20(11):1511-22. PubMed ID: 24777276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Stewart T; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Duquette P; Girard M; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Shaygannejad V; Hupperts R; Alroughani R; Oreja-Guevara C; Pucci E; Boz C; Lechner-Scott J; Bergamaschi R; Van Pesch V; Iuliano G; Ramo C; Taylor B; Slee M; Spitaleri D; Granella F; Verheul F; McCombe P; Hodgkinson S; Amato MP; Vucic S; Gray O; Cristiano E; Barnett M; Sanchez Menoyo JL; van Munster E; Saladino ML; Olascoaga J; Prevost J; Deri N; Shaw C; Singhal B; Moore F; Rozsa C; Shuey N; Skibina O; Kister I; Petkovska-Boskova T; Ampapa R; Kermode A; Butzkueven H; Jokubaitis V; Kalincik T;
    Mult Scler; 2017 Feb; 23(2):266-276. PubMed ID: 27055805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
    Kalincik T; Vivek V; Jokubaitis V; Lechner-Scott J; Trojano M; Izquierdo G; Lugaresi A; Grand'maison F; Hupperts R; Oreja-Guevara C; Bergamaschi R; Iuliano G; Alroughani R; Van Pesch V; Amato MP; Slee M; Verheul F; Fernandez-Bolanos R; Fiol M; Spitaleri DL; Cristiano E; Gray O; Cabrera-Gomez JA; Shaygannejad V; Herbert J; Vucic S; Needham M; Petkovska-Boskova T; Sirbu CA; Duquette P; Girard M; Grammond P; Boz C; Giuliani G; Rio ME; Barnett M; Flechter S; Moore F; Singhal B; Bacile EA; Saladino ML; Shaw C; Skromne E; Poehlau D; Vella N; Spelman T; Liew D; Kilpatrick TJ; Butzkueven H;
    Brain; 2013 Dec; 136(Pt 12):3609-17. PubMed ID: 24142147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of relapses in multiple sclerosis.
    Vollmer T
    J Neurol Sci; 2007 May; 256 Suppl 1():S5-13. PubMed ID: 17346747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disability and prognosis of relapsing remitting multiple sclerosis, is it different in Iraqi patients?
    Hasan ZN
    Neurosciences (Riyadh); 2011 Jul; 16(3):233-6. PubMed ID: 21677613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Novotna M; Paz Soldán MM; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Aug; 85(8):722-9. PubMed ID: 26208962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific clinical phenotypes in relapsing multiple sclerosis: The impact of relapses on long-term outcomes.
    Scott TF; Gettings EJ; Hackett CT; Schramke CJ
    Mult Scler Relat Disord; 2016 Jan; 5():1-6. PubMed ID: 26856936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic indicators for long-term disability in multiple sclerosis patients.
    Damasceno A; Von Glehn F; Brandão CO; Damasceno BP; Cendes F
    J Neurol Sci; 2013 Jan; 324(1-2):29-33. PubMed ID: 23073568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does pregnancy alter the long-term course of multiple sclerosis?
    Karp I; Manganas A; Sylvestre MP; Ho A; Roger E; Duquette P
    Ann Epidemiol; 2014 Jul; 24(7):504-8.e2. PubMed ID: 24935463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
    Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
    Lage MJ; Carroll CA; Fairman KA
    J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review.
    Kalincik T
    Neuroepidemiology; 2015; 44(4):199-214. PubMed ID: 25997994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.